Enliven Therapeutics Statistics Share Statistics Enliven Therapeutics has 59.24M
shares outstanding. The number of shares has increased by 24.88%
in one year.
Shares Outstanding 59.24M Shares Change (YoY) 24.88% Shares Change (QoQ) 20.38% Owned by Institutions (%) 99.99% Shares Floating 38.15M Failed to Deliver (FTD) Shares 25,500 FTD / Avg. Volume 4.91%
Short Selling Information The latest short interest is 4.94M, so 8.35% of the outstanding
shares have been sold short.
Short Interest 4.94M Short % of Shares Out 8.35% Short % of Float 11.89% Short Ratio (days to cover) 13.11
Valuation Ratios The PE ratio is -11.9 and the forward
PE ratio is -9.48.
Enliven Therapeutics's PEG ratio is
1.99.
PE Ratio -11.9 Forward PE -9.48 PS Ratio 0 Forward PS 165939 PB Ratio 3.42 P/FCF Ratio -14.46 PEG Ratio 1.99
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Enliven Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 19.99,
with a Debt / Equity ratio of 0.
Current Ratio 19.99 Quick Ratio 19.99 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.44M Employee Count 62 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -232K Effective Tax Rate 0.26%
Stock Price Statistics The stock price has increased by -8.67% in the
last 52 weeks. The beta is 1.03, so Enliven Therapeutics's
price volatility has been higher than the market average.
Beta 1.03 52-Week Price Change -8.67% 50-Day Moving Average 20.45 200-Day Moving Average 20.85 Relative Strength Index (RSI) 48.89 Average Volume (20 Days) 518,988
Income Statement
Revenue n/a Gross Profit -317K Operating Income -104.55M Net Income -89.02M EBITDA -88.47M EBIT -88.79M Earnings Per Share (EPS) -1.89
Full Income Statement Balance Sheet The company has 124.12M in cash and 0 in
debt, giving a net cash position of 124.12M.
Cash & Cash Equivalents 124.12M Total Debt n/a Net Cash n/a Retained Earnings -243.47M Total Assets 503.89M Working Capital 480.41M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -73.19M
and capital expenditures -44K, giving a free cash flow of -73.24M.
Operating Cash Flow -73.19M Capital Expenditures -44K Free Cash Flow -73.24M FCF Per Share -1.56
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ELVN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ELVN is $42,
which is 109.9% higher than the current price. The consensus rating is "Buy".
Price Target $42 Price Target Difference 109.9% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 24, 2023. It was a
backward
split with a ratio of 1:4.
Last Split Date Feb 24, 2023 Split Type backward Split Ratio 1:4
Scores Altman Z-Score 47.73 Piotroski F-Score 2
